Condition
Stage IV Cancer
Total Trials
4
Recruiting
0
Active
0
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (2)
P 1 (1)
P 4 (1)
Trial Status
Enrolling By Invitation2
Completed1
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT07639268Not ApplicableEnrolling By Invitation
Caregivers-Patients Support to Cope With Advanced-Cancer (CASA) Pilot Study.
NCT06883058Not ApplicableEnrolling By Invitation
Caregivers-Patients Support Coping With Advanced-Cancer (CASA) Intervention
NCT03475589Phase 4UnknownPrimary
Study on the Adverse Drug Reactions (ADRs) of Apatinib and Their Biomarker Correlations
NCT00691548Phase 1CompletedPrimary
Non-invasive Imaging of Cetuximab-Zr. 89 Uptake Wit PET: a Phase I Trial in Stage IV Cancer Patients
Showing all 4 trials